Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Rosell

Showing results (31-40 of 565) with videos related to

Pageof 57
Sort By:
Ebiomedicine|July 3, 2015
Evaluation of Biomarkers for HER3-targeted Therapies in CancerNiki Karachaliou, Rafael Rosell
Expert Opinion on Biological Therapy|December 4, 2003
World conference on lung cancerEnriqueta Felip, Rafael Rosell
Therapeutic Advances in Medical Oncology|April 6, 2018
Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challengesNiki Karachaliou, Rafael Rosell
The Lancet. Oncology|November 10, 2016
RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancerRafael Rosell, Niki Karachaliou
Lancet (London, England)|January 19, 2016
Large-scale screening for somatic mutations in lung cancerRafael Rosell, Niki Karachaliou
The Lancet. Oncology|January 17, 2022
Promising outlook with sugemalimab in non-small-cell lung cancerRafael Rosell, Peng Cao
Ebiomedicine|October 10, 2018
Rhomboids and regulation of receptor tyrosine kinase ligands sheddingNiki Karachaliou, Rafael Rosell
Cancer Discovery|September 13, 2012
A genetic snapshot of small cell lung cancerRafael Rosell, Luciano Wannesson
The Oncologist|September 28, 2012
Single nucleotide polymorphisms (SNPs) in non-small cell lung cancer (NSCLC) patientsRafael Rosell, Jia Wei
Annals of Palliative Medicine|April 6, 2015
Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitorsNiki Karachaliou, Rafael Rosell
Pageof 57

Showing results (31-40 of 565) with videos related to

Sort By:
Pageof 57
Ebiomedicine|July 3, 2015
Evaluation of Biomarkers for HER3-targeted Therapies in CancerNiki Karachaliou, Rafael Rosell
Expert Opinion on Biological Therapy|December 4, 2003
World conference on lung cancerEnriqueta Felip, Rafael Rosell
Therapeutic Advances in Medical Oncology|April 6, 2018
Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challengesNiki Karachaliou, Rafael Rosell
The Lancet. Oncology|November 10, 2016
RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancerRafael Rosell, Niki Karachaliou
Lancet (London, England)|January 19, 2016
Large-scale screening for somatic mutations in lung cancerRafael Rosell, Niki Karachaliou
The Lancet. Oncology|January 17, 2022
Promising outlook with sugemalimab in non-small-cell lung cancerRafael Rosell, Peng Cao
Ebiomedicine|October 10, 2018
Rhomboids and regulation of receptor tyrosine kinase ligands sheddingNiki Karachaliou, Rafael Rosell
Cancer Discovery|September 13, 2012
A genetic snapshot of small cell lung cancerRafael Rosell, Luciano Wannesson
The Oncologist|September 28, 2012
Single nucleotide polymorphisms (SNPs) in non-small cell lung cancer (NSCLC) patientsRafael Rosell, Jia Wei
Annals of Palliative Medicine|April 6, 2015
Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitorsNiki Karachaliou, Rafael Rosell
Pageof 57